PMID- 33791199
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20210402
IS  - 2234-943X (Print)
IS  - 2234-943X (Electronic)
IS  - 2234-943X (Linking)
VI  - 11
DP  - 2021
TI  - Characteristics of Early Death in Patients With Localized Nasopharyngeal Cancer: 
      A Population-Based SEER Analysis.
PG  - 580220
LID - 10.3389/fonc.2021.580220 [doi]
LID - 580220
AB  - Localized nasopharyngeal cancer (NPC) is a highly curable disease, but the 
      prognosis of certain cases is still poor. Distinguishing patients with a poor 
      outcome is necessary when developing therapeutic strategies. The aim of this 
      study was to investigate the characteristics of early death (ED) among patients 
      with localized NPC, and to identify independent predictors of ED. Patients 
      diagnosed with localized NPC were included from the Surveillance, Epidemiology, 
      and End Results dataset, and univariate and multivariate logistic regression 
      analyses were performed to identify ED predictors. A total of 752 patients with 
      localized NPC were enrolled, including 198 cases of ED and 480 long-term 
      survivors. Older age, unmarried status, and white race were risk factors for ED, 
      whereas diagnosis in the recent period and undifferentiated non-keratinizing 
      histology type were protective factors. In addition, for older patients, women 
      and those without radiation treatment, there was less ED for married patients 
      than unmarried patients. In conclusion, this population-based study provides an 
      overview of the characteristics of ED patients with localized NPC. Age, race, 
      marital status, year of diagnosis and histology type are risk factors for ED. 
      Moreover, married patients are at a significantly lower risk of ED. This 
      protective effect is especially pronounced in older people, women and those 
      without radiation treatment.
CI  - Copyright (c) 2021 Chen, Huang, Chen, Li, Zhao and Wei.
FAU - Chen, Haiyan
AU  - Chen H
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, China.
AD  - Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry 
      of Education, The Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, China.
FAU - Huang, Zhiheng
AU  - Huang Z
AD  - Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry 
      of Education, The Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, China.
AD  - Department of Otorhinolaryngology, The Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, China.
FAU - Chen, Liubo
AU  - Chen L
AD  - Department of Colorectal Surgery and Oncology, Key Laboratory of Cancer 
      Prevention and Intervention, Ministry of Education, The Second Affiliated 
      Hospital, Zhejiang University School of Medicine, Hangzhou, China.
FAU - Li, Yanlin
AU  - Li Y
AD  - College of Science, Hangzhou Normal University, Hangzhou, China.
FAU - Zhao, Tiehong
AU  - Zhao T
AD  - College of Science, Hangzhou Normal University, Hangzhou, China.
FAU - Wei, Qichun
AU  - Wei Q
AD  - Department of Radiation Oncology, The Second Affiliated Hospital of Zhejiang 
      University School of Medicine, Hangzhou, China.
AD  - Cancer Institute, Key Laboratory of Cancer Prevention and Intervention, Ministry 
      of Education, The Second Affiliated Hospital of Zhejiang University School of 
      Medicine, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20210310
PL  - Switzerland
TA  - Front Oncol
JT  - Frontiers in oncology
JID - 101568867
PMC - PMC8006381
OTO - NOTNLM
OT  - Surveillance Epidemiology and End Results (SEER) program
OT  - characteristics
OT  - early death
OT  - localized stage
OT  - nasopharyngeal cancer
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2021/04/02 06:00
MHDA- 2021/04/02 06:01
PMCR- 2021/01/01
CRDT- 2021/04/01 06:30
PHST- 2020/07/05 00:00 [received]
PHST- 2021/02/01 00:00 [accepted]
PHST- 2021/04/01 06:30 [entrez]
PHST- 2021/04/02 06:00 [pubmed]
PHST- 2021/04/02 06:01 [medline]
PHST- 2021/01/01 00:00 [pmc-release]
AID - 10.3389/fonc.2021.580220 [doi]
PST - epublish
SO  - Front Oncol. 2021 Mar 10;11:580220. doi: 10.3389/fonc.2021.580220. eCollection 
      2021.